FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer
- 31 March 2006
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (2) , 231-237
- https://doi.org/10.1016/j.ejso.2005.11.018
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Bladder cancerCurrent Opinion in Oncology, 2005
- FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell CarcinomaCancer Research, 2004
- Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeJournal of Clinical Oncology, 2003
- The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder CancerJournal of Urology, 2003
- Fibroblast Growth Factors and Their Receptors in Transitional Cell CarcinomaJournal of Urology, 2003
- Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladderCancer, 2002
- No evidence of somatic FGFR3 mutation in various types of carcinomaOncogene, 2001
- Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) TumorsThe American Journal of Pathology, 2001
- Can biological markers predict recurrence and progression of superficial bladder cancer?Current Opinion in Urology, 2000
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998